Mental Health Update Flashcards

1
Q

What are the common s/e of atypical antipsychotics? (7)

A

Metabolic effects
Anticholinergic
QT prolongation
Lowered seizure threshold
Antiadrenergics
NMS
Sedation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What the common s/e of typical antipsychotics medicines. (7)

A

EPSE
Anticholinergics
QT prolongation
Lowers seizure threshold
Antiadrenergic
NMS
Sedation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What are the investigations before starting therapies? (9)

A

Weight
Waist circumference
Pulse + BP
Fasting BM
HbA1c
Prolactin levels
Movement disorders
Nutritional status, diet and physical activities.
ECG

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What are the investigations during therapies? (5)

A

Tx response
Symptom/behavioural changes.
S/e
Weight
Adherence
Physical health (CV)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What antipsychotic gives the least risk of psychosis? (1)

A

Aripiprazole

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What is GASS? (1)

A

Glasgow Antipsychotic S/E scale:
- Self reporting questionnaire aims to identify s/e of antipsychotic medication.
- Consists of 22 questions with assigned points based on answers given by the px.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What is NMS? (2)

A

Life-threatening neurological disorder caused by ADR to neuroleptics/antipsychotics drugs.

Disorder develops within the 1st 2 weeks of tx with the drug but disorder can develop at any time during the tx period. Can occur in people taking anti-Parkinsonism.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What are the symptoms of NMS? (6)

A

High fever
Sweating
Unstable BP
Stupor
Muscular rigidity
Autonomic dysfunction

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What are the main features of anti-psychotic induced hyperprolactinaemia? (4)

A

Hyperprolactinaemia: Endocrine disorder but can be associated with significant morbidity.
Presents as menstrual problems in women and sexual problems in men.
Persistent asymptomatic hyperprolactinaemia can be linked to long-term physical morbidity e.g. OP and breast cancer.
Hyperprolactinaemia managed asymptomatically.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Give e.g. of an antipsychotic that has the least risk of inducing hyperprolactinaemia. (1)

A

Aripiprazole

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What are the main features of Clozapine? (5)

A

Used when px is unresponsive to or intolerant of conventional antipsychotic drugs.
If px misses 48 hrs or more of Clozapine dose, the clozapine must be discontinued and slowly re-titrated.
Potentially fatal risk of intestinal obstruction, faecal impact ion and paralytic ileus.
Neutropenia and agranulocytosis reported.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Give e.g. of clinical situations that can increase the risk of Clozapine toxicity. (5)

A

Px stops smoking or switches or an e-cigarette.
Concomitant medicines may interact to increase clozapine levels
Patient has pneumonia or other serious infection.
Reduced Clozapine metabolism is suspected.
Toxicity is suspected.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What monitoring is considered to manage Clozapine toxicity? (1)

A

Blood concentration levels carried out in addition to required blood tests to manage risk of agranulocytosis.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What factors are considered for antidepressants? (7)

A

Choice
Initiation
Adjuvants
Non-drug Tx
Risk in OD
Counselling
S/E

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What are the key s/e of SSRI’s? (7)

A

Insomnia/Anxiety/Agitation
GI bleeding
Sexual dysfunction
5-HT syndrome
Suicidal thoughts
FINISH withdrawal
Physiological symptoms

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What are the key s/e of TCA? (4)

A

Anti-histamine
Anti-adrenergic
Anti-cholinergic
Cardiac

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

What are the key s/e of MAOIs? (6)

A

Hypertensive crisis
Postural hypotension
Anti-cholinergic
5-HT syndrome
Hepatotoxicity (phenelzine)
Weight gain

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

What is FINISH? (6)

A

Discontinuation syndrome.
Flu-like symptoms
Insomnia
Nausea
Imbalance
Sensory disturbances
Hyperarousal (anxiety/agitation)

19
Q

What are the key s/e of Venlafaxine? (5)

A

Cardiac effects
Blood dyscrasias/ Bleed risk
SIADH
Suicidal behaviour
Withdrawal syndrome

20
Q

What are the key s/e of Reboxetine? (6)

A

Cardiac effects
Hyponatraemia
Hypokalaemia on prolonged tx
Suicidal behaviour
Urinary retention
Impaired vision (caution in glaucoma)

21
Q

What are the key s/e of Moclobemide? (3)

A

Lower risk of hypertensive crisis
Troublesome interactions (< MAOI)
Hyponatraemia

22
Q

What are the key s/e of Mirtazapine? (6)

A

Not many antimuscarinic effects.
Sedating
Blood disorders
Withdrawal syndrome
Weight gain
Psychotic symptoms

23
Q

What are the common s/e of general antidepressants? (5)

A

Potential for an initial increase in agitation, anxiety on starting tx.
Hyponatraemia
Sexual dysfunction
Withdrawal effects
Bleeding risk

24
Q

Explain the main features of Hyponatraemia with antidepressants. (9)

A

SSRI = high risk.
Common in elderly.
Symptoms: LOW SODIUM
Occurs within 30 days of starting antidepressants but can take months.
Can be transient or persistent
If identified, stop antidepressant and sodium levels should normalised within 1-2 weeks.
Urgent care if severe (<125mmol/L)
Withdrawal symptoms can occur (less likely at beginning of tx)

25
Q

What are the main features of SSRI/SNRI and bleeding risk? (1)

A

Reducing 5-HT uptake by platelets. SSRI reduces ability of platelets to aggregate and increase risk of haemorrhage, particularly GI bleeding.

26
Q

What factors can increase the bleeding risk when taking SSRI/SNRI? (4)

A

Elderly
Px with Hx of peptic ulcers
Alcohol excess
Co-administration with other drugs associated with bleeding risk (NSAIDs, Antiplatelets, CS, Warfarin)

27
Q

What factors can reduce the risk of bleeding when taking SSRI/SNRI? (4)

A

Avoid SSRI/SNRI
Avoid concomittant drugs
If no suitable alternative can be found, consider GI protection.
NICE suggests GI protection in older px who are taking NSAIDs/Aspirin.

28
Q

What are the cautions and c/i of antidepressants? (3)

A

CVD disease + QT prolongation:
- Antidepressant can cause QT prolongation.
- Medication Hx, Lab monitoring and baseline ECG necessary to identify px at risk for QT prolongation before starting an antidepressant that may prolong QT interval.
- Significant QT prolongation can occur through drug-drug interactions where another medication known to affect QT interval is used concomittantly or when a medication alters the metabolism of another drug which is known to affect the QT interval. Considered when new medications are added, even for short-term use e.g. ABx/Antiemetics.

29
Q

What are the risk factors of QT interval prolongation? (8)

A

Cardiac conditions e.g. bradycardia, MI/HF.
Electrolyte disturbances e.g. hypokalaemia/hypomagnesemia/hypocalcaemia.
Female
Genetic Polymorphisms
Age > 65 yrs
Congenital long QT syndrome or other inherited cardiac abnormalities.
Concomittant medication or disease states.that prolong QT interval or affect electrolytes (e.g. diuretics, renal dysfunction.)
Hx of QT prolongation

30
Q

What does MHRA drug safety state about the use of Citalopram + Escitalopram? (7)

A

Associated with dose-dependent QT interval prolongation. Avoid use in:
- Congenital long QT syndrome
- Known pre-existing QT interval prolongation
- Combination with other medicines that prolong QT interval.

ECG for px with cardiac disease.
Electrolyte disturbances corrected prior tx.

Citalopram max daily dose: 40mg (adults), 20mg (> 65 yrs), 20mg (hepatic impairment)

Escitalopram max dose: > 65 yrs reduced to 10mg/day.

Dose reduction in first 2 weeks of tx is recommended in px with mild/moderate hepatic impairment or poor metabolisers of CYP2C19 (e.g. Omeprazole). GI protection with SSRI in px at risk of bleeds.

31
Q

What is the general relationship between antidepressants and # risk? (1)

A

High risk of # for using TCA / SSRI.

32
Q

What does MHRA/CHM state about the use of SSRI/SNRI? (1)

A

SSRI/SNRI antidepressants have a small risk of postpartum haemorrhage when used in the month before delivery.

33
Q

What are the characteristics of 5-HT syndrome? (3)

A

Altered mental status
Neuromuscular Hyperactivity
Autonomic Instability

34
Q

What are the symptoms of 5-HT syndrome? (4)

A

Agitation
Confusion
Delirium
Hallucinations

35
Q

What are the neuromuscular features of 5-HT syndrome? (5)

A

Profound shivering
Tremor
Teeth Grinding
Myoclonus
Hyperreflexia

36
Q

What are the signs of autonomic instability? (7)

A

Tachycardia
Fever
Hypertension/Hypotension
Flushing
Diarrhoea
Vomiting

37
Q

What are the signs of severe 5-HT syndrome? (7)

A

Drowsiness
Coma
Seizures
Hyperthermia
Rhabdomyolysis
Renal Failure
Coagulopathies

38
Q

What factors can increase the risk 5-HT syndrome? (2)

A

Concomittant use of antidepressants with other 5-HT drugs (Tramadol, triptans)
Dopaminergic drugs (selegiline)
Close monitoring is advised if co-Rx, alternative drugs are considered.

39
Q

What is common s/s of 5-HT syndrome? (7)

A

SHIVERS:
- Shivering
- Hyperreflexia
- Increased temp
- Vital signs abnormal
- Encephalopathy
- Restlessness
- Sweating

40
Q

Which antidepressants has an overdose risk? (2)

A

TCA
Venlafaxine

41
Q

Explain the process of antidepressant withdrawal. (2)

A

When stopping an antidepressant, gradually reduce dose over 4 weeks. Some people may need longer periods e.g. drugs with shorter half-life (Paroxetine/Venlafaxine)
Not required for fluoxetine (long half life)

42
Q

What are the common interactions with antidepressants? (8)

A

High risk of QT prolongation
CYP45O inhibitors/inducers
5-HT syndrome
High bleeding risk
Warfarin
Anticonvulsants effect
Sedation risk (TCA)
Anticholinergics s/e (TCA)

43
Q

What are the main features of MAOI? (8)

A

Used when no response to other antidepressants.
May be useful in px refractory to other tx.
Food/drug interactions
E.g. Phenelzine, Isocarboxacid, Tranylcypromine, Moclobemide (reversible MAOI with less s/e)
Withdrawal symptoms
Can cause hepatic impairment.
May carry a MAOI tx card.

44
Q

What type of ADR can occur when taking MAOI? (1)

A

Hypertensive crisis s/e which can be fatal can occur if an MAOI is taken with food or drink that has high tyramine content